Clinical Trials on Generalized Epidermolysis Bullosa Simplex in New Zealand

Total 15 results

Lenus Therapeutics, LLC

Terminated

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa (CELEB)

Dystrophic Epidermolysis Bullosa | Junctional Epidermolysis Bullosa

United States
Castle Creek Pharmaceuticals, LLC

Terminated

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Epidermolysis Bullosa Simplex

United States, Israel, Australia, Austria, France, Germany, Netherlands, United Kingdom
Phoenix Tissue Repair, Inc.
Phoenix Tissue Repair, a BridgeBio company

Completed

Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)

Recessive Dystrophic Epidermolysis Bullosa

United States
Columbia University

Terminated

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) (RDEB)

Epidermolysis Bullosa

United States
Premier Specialists, Australia

Unknown

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Epidermolysis Bullosa Simplex | Epidermolysis Bullosa Simplex Kobner | Weber-Cockayne Syndrome

Australia
Organogenesis

Terminated

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa, Junctional

United States
Shire

Completed

Short Term Observational Study in DEB Patients

Dystrophic Epidermolysis Bullosa

United States, Czechia, Italy, Austria, Australia, France, Germany
Amicus Therapeutics

Completed

Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa

Epidermolysis Bullosa

United States
Scioderm, Inc.
Amicus Therapeutics

Completed

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

United States
Scioderm, Inc.
Food and Drug Administration (FDA); Amicus Therapeutics

Terminated

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

United States
Scioderm, Inc.
Amicus Therapeutics

Completed

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

Italy, Spain, Serbia, United States, Australia, Netherlands, Austria, Germany, Israel, Lithuania, France, United Kingdom, Poland
Amryt Research Limited

Completed

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa (EASE)

Epidermolysis Bullosa

United States, Spain, Israel, Australia, France, Denmark, Switzerland, Italy, Hong Kong, Argentina, Austria, Brazil, Chile, Colombia, Czechia, Georgia, Germany, Greece, Hungary, Ireland, Romania, Russian Federation, Serbia, Singapore, U... and more
Scioderm, Inc.
Amicus Therapeutics

Terminated

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

Epidermolysis Bullosa

Poland, Spain, Serbia, Netherlands, United States, Austria, Australia, Israel, Germany, France, United Kingdom, Lithuania
Pfizer

Completed

Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.

Epilepsy | Epilepsy, Generalized | Seizures | Epilepsies, Partial | Epilepsy, Complex Partial

United States
Jazz Pharmaceuticals

Recruiting

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Tuberous Sclerosis Complex | Dravet Syndrome | Lennox Gastaut Syndrome

United States

Clinical Trials on Generalized Epidermolysis Bullosa Simplex in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations